Last reviewed · How we verify
Chlordemethyldiazepam (DELORAZEPAM)
Chlordemethyldiazepam (generic name: DELORAZEPAM) is a delorazepam drug. It is currently in Phase 2 development.
Delorazepam works by enhancing the activity of the neurotransmitter GABA, which helps to calm excessive neuronal activity in the brain.
Chlordemethyldiazepam is a small molecule with unknown efficacy in treating Anorexia Nervosa and Bulimia Nervosa, as indicated by ClinicalTrials.gov. It has been studied in combination with Cognitive Behavioral Therapy, individual psychology brief psychotherapy, and olanzapine, but its exact mechanism of action is not specified in the available data.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
CNS / neurology attrition
-3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | DELORAZEPAM |
|---|---|
| Drug class | delorazepam |
| Target | GABA-A receptor alpha-1/beta-2/gamma-2, GABA-A receptor; anion channel |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | Phase 2 |
Mechanism of action
Imagine your brain is like a busy city with lots of cars (neurons) moving around. GABA is like a traffic cop that helps slow down the traffic when it gets too busy. Delorazepam helps the traffic cop do its job more effectively, which can help reduce anxiety and promote relaxation.
Approved indications
Common side effects
- Sopor
- Drug abuse
- Intentional self-injury
- Bradyphrenia
- Suicide attempt
- Toxicity to various agents
- Overdose
- Bradykinesia
- Intentional product misuse
- Psychomotor hyperactivity
- Poisoning
- Coma
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Chlordemethyldiazepam CI brief — competitive landscape report
- Chlordemethyldiazepam updates RSS · CI watch RSS
Frequently asked questions about Chlordemethyldiazepam
What is Chlordemethyldiazepam?
How does Chlordemethyldiazepam work?
What is the generic name of Chlordemethyldiazepam?
What drug class is Chlordemethyldiazepam in?
What development phase is Chlordemethyldiazepam in?
What are the side effects of Chlordemethyldiazepam?
What does Chlordemethyldiazepam target?
Related
- Drug class: All delorazepam drugs
- Target: All drugs targeting GABA-A receptor alpha-1/beta-2/gamma-2, GABA-A receptor; anion channel
- Therapeutic area: All drugs in Neuroscience
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing